Table 5. Summary of the effects of SAR218645 in in vivo models.
| Model | Species | Dose-range (mg/kg), route | Minimal active dose (mg/kg) |
|---|---|---|---|
| Functional assays | |||
| LY404039-induced turning behavior | CD-1 mice | 1–10, po | 3 |
| DOI-induced glutamate release in the medial prefrontal cortex | Sprague-Dawley rats | 0.3–30, po | 3 |
| Schizophrenia | |||
| DOI-induced head-twitch behaviors | CD-1 mice | 1–10, po | 3 |
| MK-801-induced hyperactivity | Swiss mice | 0.1–10, po | >10 |
| Amphetamine-induced hyperactivity | Swiss mice | 0.1–10, po | >10 |
| Hyperactivity | NMDA Nr1neo−/− mice | 1–10, po | >10 |
| Hyperactivity | DAT−/− mice | 3–10, po | >10 |
| Conditioned Avoidance Response | C57BL/6J mice | 0.01–1, po | >10 |
| Novel object recognition task | Swiss mice | 0.01–1, po | 0.01 |
| Y-maze test | NMDA Nr1neo−/− mice | 0.1, po | 0.1 |
| Amphetamine-induced disrupted latent inhibition | C57BL/6J mice | 0.1–10, po | 1 |
| Amphetamine-induced disruption of auditory evoked potentials | Sprague-Dawley rats | 0.3–3, po | 0.3 |
| Side-effects | |||
| Catalepsy | Sprague-Dawley rats | 30, po | >30 |
| 6-Hz-electroshock-induced seizures | OF1 mice | 10–30, ip | >30 |
| Maximal-electroshock-induced seizures | OF1 mice | 30, ip | >30 |
| Pentylenetetrazol seizure threshold | OF1 mice | 10–30, po | >30 |